Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando.
"We look forward to sharing new data for ruxolitinib cream (Opzelura®) across multiple indications, including prurigo nodularis, and axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD) at this year's AAD Annual Meeting,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. "Incyte’s active participation in this key congress reinforces our commitment to addressing critical needs in dermatology while fostering meaningful dialogue with researchers, patients and advocates to inform the development of innovative treatments.”
Key abstracts include:
Late-Breaking Oral Presentation
Prurigo Nodularis (PN)
Efficacy and Safety of Ruxolitinib Cream in Patients With Prurigo Nodularis: Results From a Phase 3, Randomized, Vehicle-Controlled Study (TRuE-PN1)
(Session: S028 – Late-Breaking Research: Session 1. Saturday, March 8, 2025, 9:24 a.m. ET)
ePoster Exhibits
Atopic Dermatitis (AD)
Long-Term Safety of Ruxolitinib Cream in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Adverse Events of Interest from the TRuE-AD1 and TRuE-AD2 Phase 3 Studies (Abstract: #64524)
Association of Ruxolitinib Cream Initiation with Reduction in Use of Other Topical Treatments, Oral Corticosteroids, and Biologics for Atopic Dermatitis, Regardless of Previous Use of Biologics (Abstract: #64526)
52-Week Disease Control and Safety with As-Needed Application of Ruxolitinib Cream in Children Aged 2 to 11 Years with Moderate and/or More Extensive Atopic Dermatitis: Subgroup Analysis from the TRuE-AD3 Study (Abstract: #64656)
Ruxolitinib Cream Demonstrated Long-Term Disease Control and Quality of Life Benefits in Adults and Adolescents with Mild to Moderate Atopic Dermatitis (Abstract: #64727)
Graft-Versus-Host Disease (GVHD)
Axatilimab for Patients with Dermatologic Manifestations of Chronic Graft-Versus-Host Disease: A Post Hoc Analysis (Abstract: #64616)
More information regarding the 2025 AAD Annual Meeting can be found at: https://www.aad.org/member/meetings-education/am25.
About Opzelura® (ruxolitinib) Cream 1.5%
Opzelura, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, is the first and only treatment for repigmentation approved for use in the United States. Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended.
In Europe, Opzelura (ruxolitinib) cream 15mg/g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura.
Opzelura and the Opzelura logo are registered trademarks of Incyte.
About Niktimvo™ (axatilimab-csfr)
Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).
In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic GVHD and any future indications.
Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256).
Niktimvo is a trademark of Incyte.
All other trademarks are the property of their respective owners.
About Povorcitinib (INCB54707)
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for vitiligo, hidradenitis suppurativa (HS) and prurigo nodularis (PN), as well as Phase 2 trials for asthma and chronic spontaneous urticaria (CSU).
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, and Incyte’s goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners’ products; the acceptance of Incyte and its partners’ products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report on form 10-K for the year ended December 31, 2024. Incyte disclaims any intent or obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227606859/en/
Contacts
Media
media@incyte.com
Investors
ir@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alipay+ Empowers New Growth Opportunities for Malaysian SMEs, Contributing More Than 80% of Inbound QR Payments via DuitNow17.3.2025 10:00:00 EET | Press release
In their first full year of partnership in 2024, Payments Network Malaysia Sdn Bhd (PayNet) and Ant International, a leading global digital payment, digitisation and financial technology provider, brought new economic opportunities to Malaysian SMEs, with Alipay+ making up more than 80 percent of cross-border inbound QR payments via DuitNow. In the peak travel season in December 2024, the partnership enabled 6 times growth in revenue for Malaysian merchants, compared to the same period in 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317987292/en/ Malaysian SMEs can connect with global customers via DuitNow QR and Alipay+ In October 2023, Alipay+, a unified wallet gateway with cross-border payment and digitisation services under Ant International, went live on DuitNow QR, enabling Malaysian SMEs to accept QR payments from international travellers. Today, the number of Alipay+ payment partners that can make payment
NTT DATA and CrowdStrike Expand Partnership to Strengthen AI-Powered Cyber Resilience17.3.2025 10:00:00 EET | Press release
NTT DATA, a global digital business and IT services leader, and CrowdStrike, a global cybersecurity leader, today announced an expanded partnership to power NTT DATA's managed cybersecurity services with the AI-native CrowdStrike Falcon® cybersecurity platform. Cyberattacks are growing faster, stealthier and more sophisticated, while the cybersecurity skills gap leaves organizations vulnerable. To protect against modern threats, clients need AI-native platform technology and the benefits of a managed security solution to reduce complexity and serve as a force multiplier for security and IT teams. By combining NTT DATA’s world-class managed services with the power of the Falcon platform, clients gain the protection they need to stop breaches. Key capabilities of the partnership include: Integrated Managed Security Services: The integration of the Falcon platform with NTT DATA’s managed services provides organizations with advanced threat detection and response across their digital envir
Appaloosa Statement Regarding SES Announcement17.3.2025 10:00:00 EET | Press release
Appaloosa LP (“Appaloosa”), which manages funds holding a more than 7% economic interest in SES S.A. (“SES” or the “Company”), today issued the following statement in response to the SES Board of Directors’ (the “Board”) March 14, 2025 announcement. “The satellite industry is evolving rapidly and, as the SES Board’s announcement makes clear, even glacial change at SES requires strong shareholder advocacy. The initial steps the SES Board is taking to modernize its structure are long-overdue and only came following shareholder pressure. However, much more can, and must, be done -- with a greater sense of urgency than is evident from the Board’s incrementalism. “Specifically, adding a director with capital markets experience should be a priority as we believe such an appointment could prompt SES to finally begin addressing its underperforming capital investment practices and return value to shareholders. Likewise, the remaining board, capital structure and governance measures outlined in
Beating The Risks of Expanding Into Emerging Market IT Channels17.3.2025 09:00:00 EET | Press release
For IT vendors, emerging markets are risky. Local regulations, cultural differences, local currencies, channel liquidity, and settling disputes complicate such plans. Fortunately, a new generation of channel finance solutions is smoothing the journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250314300371/en/ Boris Todorov, Executive Vice President of WeFi's Client Solutions Group The emerging market growth trend Emerging markets are becoming the engines powering global and regional trade, growing at an annual rate of 4.2% (IMF), versus 1.7% in mature economies, and contributing two-thirds to global growth. India's heavy investments in its technology sector, China's focus on modern healthcare, Brazil's ambitions for green energy, and the rise of mobility among African countries—digital technology enables strong growth in emerging markets. Technology vendors are changing how they tap into those markets through supporting
Bureau Veritas Strengthens Its Leading Position in the Chilean Copper Market Through the Acquisition of GeoAssay17.3.2025 08:30:00 EET | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces the acquisition of GeoAssay. This transaction cements Bureau Veritas’ position as the Metals & Minerals market leader in Chile, the world’s largest copper producer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250316180459/en/ Hinda Gharbi, Chief Executive Officer at Bureau Veritas Bureau Veritas’ Metals & Minerals operations aim to support our clients throughout the entire mining cycle, from mine to port. This is achieved by accurately determining the physical, chemical and geochemical properties of materials through our extensive network of laboratories. With a global presence in major ports around the world and with global mining and refining locations, Bureau Veritas’ footprint is expanding in this resource-rich region. GeoAssay specializes in copper, an essential mineral for energy transition at scale. Capabilities incl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom